A Step Forward for Precision Equity in Kidney Disease-Reference-Cited by-同舟云学术

A Step Forward for Precision Equity in Kidney Disease

Published:2023-03-16 Issue:11 Volume:388 Page:1043-1044
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Powe Neil R.¹

Affiliation:

1. From the University of California, San Francisco, and the Priscilla Chan and Mark Zuckerberg San Francisco General Hospital, San Francisco.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMe2301003

Reference10 articles.

1. Racial Differences in the Incidence of Treatment for End-Stage Renal Disease

2. Incidence, prevalence, patient characteristics, and treatment modalities. In: 2022 USRDS annual data report: end stage renal disease. Bethesda, MD: National Institutes of Health, 2022 (https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/1-incidence-prevalence-patient-characteristics-and-treatment-modalities).

3. The Pathogenesis of Race and Ethnic Disparities

4. Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Race, Health Care Algorithms, and Precision Health Equity;Annals of Internal Medicine;2024-04

2. Evaluating ApoL1 Genetic Testing Policy Options for Transplant Centers;Clinical Journal of the American Society of Nephrology;2024-01-08

3. Care of the Patient With Abnormal Kidney Test Results;Annals of Internal Medicine;2023-05

4. Inhibiting APOL1 to Treat Kidney Disease;New England Journal of Medicine;2023-03-16

5. Evolution-informed therapy for kidney disease;Evolution, Medicine, and Public Health;2023-01-01